ClinicalTrials.gg
CompletedNCT00351143Updated Sep 11, 2017

A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control

A Phase 4 interventional study of salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training and salmeterol/fluticasone propionate 50/250 µg in Asthma, sponsored by GlaxoSmithKline. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2005, registered Jul 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
80th of 238
274 · median 93
Started
2005
with 16 others
Phase 4
53 of 262
none open now
Registered
21st of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 80th largest by enrollment of the 238 interventional ones that give a count, is one of 17 that started in 2005, is one of 53 in phase 4, and was the 21st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study will investigate whether study subjects with previously uncontrolled asthma treated with SERETIDE Diskus 50/250 CCI18781+GR33343 mcg twice a day can attain a level of Total Control of their condition and whether adherence to treatment can be enhanced by teaching the subjects. Two groups of equal size with identical medical treatment will be compared with each other, the test group receiving three training modules during study visits and the control group regular study visits only.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • QoL
  • Asthma
  • asthma compliance enhancement
  • Salmeterol/fluticasone
  • Total control
  • SERETIDE
  • FEV1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with persistent asthma.
  • Not treated with the combination of a ICS (inhaled )and a LABA (long-acting beta-agonist).
  • Female subjects must not be fertile or must use effective .
  • Subject must be able to comply with the use of the questionnaires in the local language.

Exclusion criteria

Exclusion criteria:

  • Known or suspected .
  • Pregnant or lactating.
  • Participating investigator, employee of an investigator, or family member of any of the aforementioned.
  • Smoking history: Pack-years > 10 years.
  • Have known clinical or laboratory evidence of a serious uncontrolled systemic disease.
  • Known to any substance contained in product or as-needed medication.
  • Treatment with oral within 2 months prior to the screening visit.
  • Upper or lower respiratory tract infection (microbiologically verified) within 1 month prior to screening visit.
  • Acute asthma exacerbation requiring hospitalisation or emergency room treatment within 3 months prior to the screening visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    Interventional group: Period 2

    Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2

    Drug: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training

  • Active comparator
    Control group: Period 2

    Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2

    Drug: salmeterol/fluticasone propionate 50/250 µg

  • Experimental
    Subjects receiving salmeterol/fluticasone propionate: Period 1

    All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1

    Drug: salmeterol/fluticasone propionate 50/250 µg

Interventions

  • Drugsalmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training

    Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.

  • Drugsalmeterol/fluticasone propionate 50/250 µg

    Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2

06

What researchers measure

Primary outcomes

  1. number of subjects who achieved Total asthma Control: Period 2

    Proportion of subjects who achieved Total Control in 7 out of the last 8 consecutive weeks in treatment period 2 with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing and compliance enhancement training compared with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing without compliance enhancement training.

    Time frame: Up to Week 24

Secondary outcomes

  1. Number of subjects who achieved Total Control with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing: Period 2

    Proportion of subjects who achieved Total Control with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing in treatment period 1 will be analyzed.

    Time frame: Up to Week 12

  2. Time to first individual week with Total Control

    Time to first individual week with Total Control in treatment period 2 will be analyzed.

    Time frame: Up to Week 24

  3. Morning peak expiratory flow (PEF)

    PEF is defined as a person's maximum speed of expiration and will be measured using a peak flow meter.

    Time frame: Up to Week 24

  4. Forced expiratory volume in one second (FEV1)

    FEV1 is defined as Forced Expiratory Volume in the first second. The volume of air that can be forced out in one second after taking a deep breath, an important measure of pulmonary function.

    Time frame: Up to Week 24

  5. Asthma symptom score

    Asthma symptom score will be analyzed to check the symptom severity

    Time frame: Up to Week 24

  6. Number of subjects using rescue medication

    Rescue medication usage will be analyzed.

    Time frame: Up to Week 24

  7. Number of nights with awakening due to asthma

    Number of nights with awakening due to asthma will be analyzed.

    Time frame: Up to Week 24

  8. Asthma severity score

    Asthma severity score will be analyzed

    Time frame: Up to Week 24

  9. Number of subjects with adverse events (AEs)

    Adverse events will be observed and counted.

    Time frame: Up to Week 24

  10. AQLQ score

    Quality of life of subjects with asthma will be analyzed.

    Time frame: Up to Week 24

07

Study locations

32 sites
  • GSK Investigational Site
    Aalborg, DK-9100, Denmark
  • GSK Investigational Site
    Aarhus C, DK-8000, Denmark
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    Kobenhavn NV, 2400, Denmark
  • GSK Investigational Site
    Naestved, 4700, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Aarau, 5000, Switzerland
  • GSK Investigational Site
    Allschwil, 4123, Switzerland
  • GSK Investigational Site
    Basel, 4001, Switzerland
  • GSK Investigational Site
    Basel, 4031, Switzerland
  • GSK Investigational Site
    Basel, 4053, Switzerland
  • GSK Investigational Site
    Basel, 4054, Switzerland
  • GSK Investigational Site
    Basel, 4058, Switzerland
  • GSK Investigational Site
    Bern, 3007, Switzerland
  • GSK Investigational Site
    Bern, 3011, Switzerland
  • GSK Investigational Site
    Bern, 3012, Switzerland
  • GSK Investigational Site
    Bever, 7502, Switzerland
  • GSK Investigational Site
    Brittnau, 4805, Switzerland
  • GSK Investigational Site
    Castione, 6532, Switzerland
  • GSK Investigational Site
    Düdingen, 3186, Switzerland
  • GSK Investigational Site
    Egg, 8132, Switzerland
  • GSK Investigational Site
    Faltigberg-Wald, 8639, Switzerland
  • GSK Investigational Site
    Horw, 6048, Switzerland
  • GSK Investigational Site
    Klosters, 7250, Switzerland
  • GSK Investigational Site
    Malvaglia, 6713, Switzerland
  • GSK Investigational Site
    Massagno, 6900, Switzerland
  • GSK Investigational Site
    Pregassona, 6963, Switzerland
  • GSK Investigational Site
    Steckborn, 8266, Switzerland
  • GSK Investigational Site
    Thun, 3600, Switzerland
  • GSK Investigational Site
    Wald, 8636, Switzerland
  • GSK Investigational Site
    Wigoltingen, 8556, Switzerland
  • GSK Investigational Site
    Worb, 3076, Switzerland
08

References and documents

Publications

  • Ulrik CS, Claudius BK, Tamm M, Harving H, Siersted HC, Backer V, Hellquist B, Dahl R, Hogholm A, Johnk IK. Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. Clin Respir J. 2009 Jul;3(3):161-8. doi: 10.1111/j.1752-699X.2009.00129.x. Erratum In: Clin Respir J. 2009 Jul;3(3):185. PubMed 20298399 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Jun 2007, 22 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 22 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2006
First posted
Jul 12, 2006
StartActual
Jul 26, 2005
Primary completionActual
Jun 13, 2007
CompletionActual
Jun 13, 2007
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00351143
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2006
Start date
Jul 26, 2005
Primary completion
Jun 13, 2007
Completion
Jun 13, 2007
Last update
Sep 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion